SHE Level 4
SCQF Credit Points 20.00
ECTS Credit Points 10.00
Module Code MHC526406
Module Leader Mark Williams
School School of Health and Life Sciences
Subject Biological and Biomedical Sciences
  • B (January start)

Pre-Requisite Knowledge

M3B126380 Systematic & Cellular Pathology or equivalent, M2C926376 Blood Science or equivalent -720

Summary of Content

This module will provide a multi-disciplinary view of blood science with relevance to specific conditions of the blood, subsequent clinical outcome and bio-markers.


Therapeutic drug monitoring Assay and interpretation of values in on-going drug therapy; identification of agent and treatment in chemical intoxication; drug abuse. Haematology and Transfusion Science Iron deficiency Anaemia, Megaloblastic anaemia; Red cell membrane disorders, Haemolytic anaemias including immune mediated destruction of blood cells and Coagulation disorders. Molecular haemopoiesis including haemopoiesis and molecular mechanisms of erythrocytosis and polycythaemia, differentiation and development, regulation by cytokines, cytokine signalling and oxygen dependent transcriptional regulation of EPO production. Haematological Malignancy Haematological malignancies (Acute leukaemia), Chronic Myeloid Leukaemias: The haemopoietic stem cell, clinical presentation, molecular biology, therapeutic options, Imatinib, drug resistance, future directions. Clinical Immunology Principles of Organ Transplantation including the Immunosuppression Role of Histocompatibility Antigens in Transplantation, and treatment of immune based transplantation reactions. The Principles of 'in -vitro' measurement of Effectors of the Immune Response. Neoplastic diseases, Immunotherapy (e.g. CAR T-cells) and Radiotherapy - clinical applications, side effects, current methodologies including vaccines, antibody and viral based therapies. Detection and Monitoring of Neoplasms Framing the problem: the need for easier but more reliable ways to detect and monitor cancers using biomarkers. What are biomarkers? The range of possible biomarkers in blood: from single analytes to complete gene-expression or protein profiles of blood cells. Biomarkers for cancer: detection and diagnosis, patient stratification for therapy, treatment response monitoring, assessing toxicity and efficacy. Biomarkers to guide and inform drug discovery and development. Barriers to biomarker adoption: legislative criteria, translation to clinical practice, health economics. The future of blood biomarkers for monitoring neoplasms.

Learning Outcomes

On successful completion of this module the student should be able to:1. Describe key mechanisms underlying haematological diseases which represent important targets for drug discovery. 2. Recognise both clinically adopted and emerging therapeutic strategies for the treatment of non-malignant and malignant diseases. 3. Explain key aspects of blood science practices in the clinic and the laboratory.

Teaching / Learning Strategy

Students gain knowledge and understanding as a result of guidance through a formal lecture programme and extensive private study supported by tutorial sessions. Enquiry based learning will be undertaken as a student-centred learning package and a data interpretation exercise. Lectures and tutorials will support broader learning via photographic and video illustration and podcasts Data interpretation and analysis sessions are an integral part of the module and students will be encouraged to critically interpret data reported in scientific publications. In preparation for the coursework exam, an online practice session is given. The students are asked to carry out this exercise in a set time period and use peer review and assessment to provide each other with feedback. Support is given via model answers as guidance in critical analysis. The SCL topic is presented through a guided reading programme and students construct their own notes by accessing the literature and answering a series of specific questions in an essay.

Indicative Reading

Recommended texts:- Therapeutic drug monitoring: newer drugs and biomarkers. Dasgupta, Amitava, 2012. (E-book in library) Janeways Immunobiology. Kenneth Murphy. 9th Edition, Garland, New York, 2016. Roitt, Brostoff and Male. Immunology, 8th Edition, Mosby, London 2012. Transfusion medicine and hemostasis: clinical and laboratory aspects 3rd edition. Beth Shaz. 2018. E-book in library. Mollison's blood transfusion in clinical medicine: 12th edition Klein, Harvey G., Publisher: John Wiley and Sons, Inc., Pub date:2014. E-book in library. Lecture Notes on Clinical Biochemistry. Beckett G et al. 9th edition Blackwell 2013 (Full text, Clinical Biochemistry also available as E-book). Clinical Biochemistry: An Illustrated text. Allan Gaw. 5th edition 2013 Churchill Livingstone Elsevier. Harmening D.M. Modern Blood Banking and Transfusion Practices, 6th Edition, Davis, 2012. Cancer immunotherapy: immune suppression and tumor growth 2nd edition. <> George C Prendergast. 2013. E-book in library. Experimental and Applied Immunotherapy. Jeffrey Medin. 2011. E-book in library. Handbook of Targeted Cancer Therapy and Immunotherapy, 2nd edition. Daniel Karp and Gerald Falchook. 2018. E-book. Additional Recommended Reading

Transferrable Skills

The students should acquire personal transferable skills such as the ability to retrieve information from scientific papers, critically analyse data presented in papers and carry out a programme of independent study. They should also gain the ability to consider different experimental approaches used to analysis scientific hypotheses.

Module Structure

Activity Total Hours
Assessment (FT) 9.00
Independent Learning (FT) 151.00
Lectures (FT) 30.00
Tutorials (FT) 10.00

Assessment Methods

Component Duration Weighting Threshold Description
Exam 01 3.00 70.00 35% Unseen written exam
Course Work 01 2.00 30.00 35% Data Analysis